Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Summary
Third Opinion Trial Synopsis:
This is a study testing a new medicine called cevostamab for people with a type of cancer called multiple myeloma. The medicine will be given through a tube in the vein and the study is looking at how much medicine is safe to give and how well it works. The study is open to people whose cancer has come back after treatment or has not responded to past treatments.
This is a study testing a new medicine called cevostamab for people with a type of cancer called multiple myeloma. The medicine will be given through a tube in the vein and the study is looking at how much medicine is safe to give and how well it works. The study is open to people whose cancer has come back after treatment or has not responded to past treatments.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: